PARP Inhibitor Biomarkers Market Analysis

PARP Inhibitor Biomarkers Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is divided into kits and assays. The kits segment of the PARP inhibitor biomarkers industry is forecasted to reach USD 1.1 million by 2032, showcasing robust growth propelled by several key factors.
 

• The increasing prevalence of cancer, particularly breast and ovarian cancers, has heightened the demand for effective treatment options such as PARP inhibitors. As these inhibitors gain prominence in oncology, the need for reliable biomarker kits to assess patient suitability for PARP inhibitor therapy grows significantly.
   
• Furthermore, the rising adoption of companion diagnostics, which are integral for determining patient eligibility for specific targeted therapies like PARP inhibitors, contributes to the increasing demand for biomarker kits.
   
• The FDA-approved myChoice CDx test from Myriad Genetics, Inc., is designed to identify patients with advanced ovarian cancer demonstrating positive homologous recombination deficiency (HRD) status. Healthcare providers and pharmaceutical companies alike recognize the value of companion diagnostics in guiding treatment decisions, thus stimulating the uptake of biomarker kits in clinical practice.
   

Based on service, the PARP inhibitor biomarkers market is bifurcated into BRCA 1 & 2 testing, HRD testing, HRR testing, and other services. The BRCA 1 & 2 testing segment accounted for USD 374.1 million in 2023.
 

• This surge can be attributed to the segment's critical role in identifying individuals at risk of hereditary breast and ovarian cancers, bolstered by growing awareness among healthcare providers and patients.
   
• The therapeutic implications of BRCA mutations, particularly in guiding treatment decisions with PARP inhibitor therapies, further fueled the demand for accurate testing services.
   
• Expanded testing guidelines, technological advancements, and supportive reimbursement policies have also contributed to the segment's remarkable performance.
   

Based on application, the PARP inhibitor biomarkers industry is bifurcated into breast cancer, ovarian cancer, and other applications. The breast cancer segment accounted for USD 409.3 million in 2023.
 

• Heightened global awareness and increased screening efforts for breast cancer have driven demand for advanced treatments like PARP inhibitors.
   
• Significant advancements in medical research have revealed the effectiveness of PARP inhibitors in targeting specific genetic mutations associated with breast cancer, leading to their widespread adoption.
   
• Moreover, the approval and commercialization of tailored PARP inhibitor drugs for breast cancer, along with supportive regulatory environments and reimbursement policies, have further fueled market growth.
   
• These factors collectively underscore the commanding position of the breast cancer segment within the market.
   

Based on end-use, the PARP inhibitor biomarkers market is bifurcated into hospitals and clinics, diagnostic laboratories, academic and research institutes, and other end-users. The hospitals and clinics segment accounted for USD 387.4 million in 2023.
 

• This prominence is primarily driven by the high clinical demand within these facilities, which serve as key points of care for patients requiring diagnosis and treatment, particularly in oncology.
   
• The presence of specialized oncology departments equipped with advanced diagnostic technologies and the preference of healthcare professionals for personalized treatment strategies further bolster this segment's significance.
   
• Additionally, hospitals and clinics possess the necessary infrastructure, resources, and established protocols for efficient biomarker testing. Patient accessibility, coupled with favorable reimbursement policies, also contribute to the segment's substantial market share.
   
• Therefore, the hospitals and clinics segment play a pivotal role in facilitating biomarker testing and subsequent treatment decisions in diseases targeted by PARP inhibitors.
   

The PARP inhibitor biomarkers industry in North America accounted for a significant revenue of USD 369.4 million in 2023, and this trajectory is set to continue upwards.
 

• The growing occurrence of cancer in the region, particularly breast and ovarian cancers, which are key focuses for PARP inhibitors, underscores the importance of precise biomarker testing to guide treatment decisions. According to the Centers for Disease Control and Prevention (CDC), annually in the U.S., approximately 240,000 instances of breast cancer are identified among women and around 2,100 among men. Breast cancer claims the lives of about 42,000 women and 500 men in the U.S. each year.
   
• Thus, with the growing prevalence of cancer, more patients are turning to genetic testing to pinpoint candidates for PARP inhibitor therapy, leading to a surge in demand for biomarker testing.
   

UK is anticipated to witness robust growth in the global market.
 

• The UK boasts a strong biomedical research infrastructure, including renowned universities, hospitals, and research institutes.
   
• Clinical trials investigating the efficacy and safety of PARP inhibitors are ongoing in the UK, contributing to the growing body of evidence supporting their use in cancer treatment. This research activity not only enhances clinical understanding but also drives the adoption of biomarker testing in clinical practice.
   

Japan market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The convergence of next-generation sequencing (NGS) and liquid biopsy technologies in Japan's healthcare landscape is driving a paradigm shift towards precision oncology, with implications for the PARP inhibitor biomarkers industry.
   
• These advancements not only enable the identification of novel biomarkers associated with PARP inhibitor response but also improve patient access to personalized treatment options.
   

South Korea PARP inhibitor biomarkers market is expected to grow significantly over the years.
 

• South Korea is witnessing an escalation in cancer incidence rates. PARP inhibitors demonstrate effectiveness in treating diverse cancers such as breast, ovarian, and prostate cancers. Estimated figures indicate that in 2020, South Korea documented around 24.9 thousand cases of breast cancer, affirming its position as one of the prevalent cancer types.
   
• With the ongoing surge in these cancer types, there arises a pressing need for cancer biomarkers capable of accurately identifying patients poised to gain the most from PARP inhibitor therapy.
   

The PARP inhibitor biomarkers industry in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The pharmaceutical industry in Saudi Arabia is expanding, with more companies entering the market and investing in research and development. This will lead to the development of new PARP inhibitors and companion diagnostic tests, further driving growth in the biomarkers testing market.